Non-Helium Magnetoencephalography in Autism Spectrum Disorder
Condition(s) studied
Investigational drug(s) / intervention(s)
Magnetoencephalography: Participants will undergo magnetoencephalography scan in both resting and tasking state.
Study summary
The goal of this observational study is to learn how brain activity in children with autism spectrum disorder (ASD) differs from typical developing children using magnetoencephalography (MEG).
The main questions this study aims to answer are:
Do children with ASD show different patterns of neural oscillation compared to typically developing children? Can MEG identify specific brain features that help ASD diagnosis?
Participants will undergo MEG scan in both resting and tasking state, and their brain activity will be analyzed for characteristic neural oscillations and connectivity patterns.
This study may help develop better tools for early ASD diagnosis.
Eligibility
Primary outcome measure(s)
- Identification of Neural Oscillation Characteristics in Children with Autism Spectrum Disorder — Baseline assessment (single time point, within 1 week of enrollment).
The primary outcome will measure group differences in neural oscillation features (e.g., spectral power and spatial distribution) across frequency bands (alpha, beta, gamma) between children with Autism Spectrum Disorder and typically developing children during resting-state and task-based conditions. Quantified using time-frequency analysis of magnetoencephalography data. Statistical analysis will include independent t-tests (or Mann-Whitney U tests for non-normally distributed data) with false discovery rate (FDR) correction, using SPSS version 27.0.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Guangzhou Women and Children's medical center | Guangzhou | Guangdong | Recruiting |
More Guangzhou Women and Children's Medical Center trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07064967 on ClinicalTrials.gov ↗ ← All trials in China